Our Company specializes in serving medical professionals in the area of critical care, anesthesiology, cardiology, surgery, radiology as well as obsteric and gynecology (O&G). Our clients include both government and private hospitals, instituitions and specialist centers.

 

Vasomedical, Inc. (NASDAQ-VASO) is the developer and marketer of EECP® external counterpulsation therapy. Since 1995, Vasomedical has been committed to providing superior solutions for the management of cardiovascular diseases through products that make improved clinical and economic outcomes possible. Through EECP, Vasomedical is providing noninvasive, atraumatic treatment for coronary artery disease, and offering new hope to patients who are poor candidates for other invasive measures.

EECP extends the ability of interventional cardiologists and cardiothoracic surgeons to treat coronary artery disease, and provides non-interventional cardiologists a means of participating in the treatment of patients who have become refractory to drugs

YB Dato Seri Suleiman Mohamed, Deputy Minister of Health, Malaysia at the Cybron EECP launch

 
 

 

EECP® treatment uses unique equipment to inflate and deflate a series of pneumatic compressive cuffs around the lower extremities. Treatment is around the lower extremities. Treatment is administered on a padded table where three sets of electronically controlled inflation and deflation valves are located. These valves are connected to specially designed adjustable cuffs that are wrapped firmly, but comfortably around the patient's calves, lower thighs, and upper thighs, including the buttocks.

 


The EECP machine

The design of the cuffs permits significant pressure to be applied to the arteries and veins at relatively low air pressures. Timing for inflation and deflation is regulated by running electrocardiogram signals through a microprocessor that monitors the treatment process.

EECP therapy is a series of one hour treatments usually performed once or twice a day and usually for a total of 35 sessions. Treatments are performed by highly trained technicians with extensive backgrounds in emergency patient care and who are certified in advanced cardiac life support.

 

 
Managing Director of Cybron Mr Thomas Ong with a volunteer

 

While the heart is at rest, the cuffs are inflated in rapid sequence from the calves upward. This creates a pressure wave that increases diastolic pressure, coronary artery perfusion pressure, and blood flow to the heart muscle.

 

This compression of the blood vessels in the legs also increases the volume of blood returned to the right side of the heart via the venous system. Instantaneous deflation of all cuffs at the onset of the heart's contraction lowers the resistance the heart must pump against, decreasing the heart's work load. This latter effect, when coupled with increased venous return, significantly raises cardiac output.

The overall effect is to increase the oxygen supply of the heart, while decreasing its oxygen demand


Click to view larger image

 

 

The body has its own (natural) solution to an inadequate blood supply caused by blocked or partially blocked arteries. When an artery is severely narrowed, the body can increase the amount of blood flowing to the heart muscle by opening up small branches of nearby arteries. Known as collateral circulation, these networks of blood vessels create new routes for blood to detour around clogged arteries.

Repeated and pulsed increases in pressure during diastole may stimulate opening or formation of collateral channels across this pressure gradient within the heart muscle, resulting in increased blood supply to deprived tissues.

The development of a collateral circulation is particularly important in the heart muscle where it may be life saving. However, the development of collateral circulation is a gradual process, and not everyone has the same ability to develop these networks.

EECP® treatment appears to stimulate the natural process of developing collateral circulation, but there are probably other, yet unexplained, mechanisms that contribute to the long-lasting effects of EECP® treatment.